Full Press Release Details
WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.
The following will be presented:
Presentation Title: "Drug Screening and CRISPR/Cas9 Screening of HCN Channels"
Poster Presentation Session: P-17
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Presentation Title: "Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency"
Poster Presentation Session: P-17
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Presentation Title: "Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort"
Poster Presentation Session: P-22
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Presentation Title: "Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study"
Poster Presentation Session: Late-Breaking Abstracts (LBA); P-31
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
For more information on SLEEP 2024, please refer to https://www.sleepmeeting.org/
About Vanda Pharmaceuticals Inc.
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
SOURCE Vanda Pharmaceuticals Inc.
21 %
more press release views with